| Trial ID: | L0307 |
| Source ID: | NCT03748628
|
| Associated Drug: |
EDP-305
|
| Title: |
Absorption, Metabolism and Excretion (AME) Study of [14C]EDP-305 in Healthy Male Subjects
|
| Acronym: |
--
|
| Status: |
Completed
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
NASH - Nonalcoholic Steatohepatitis
|
| Interventions: |
Drug: EDP-305
|
| Outcome Measures: |
Cmax of EDP-305 in plasma|AUC of EDP-305 in plasma|AUC-inf in plasma|Amount excreted in urine (Aeu)|Amount excreted in feces (Aef)|Safety measured by adverse events
|
| Sponsor/Collaborators: |
Enanta Pharmaceuticals
|
| Gender: |
Male
|
| Age: |
18 Years to 55 Years ?? (Adult)
|
| Phases: |
Phase 1
|
| Enrollment: |
8
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science
|
| Start Date: |
October 5, 2018
|
| Completion Date: |
October 13, 2018
|
| Results First Posted: |
--
|
| Last Update Posted: |
November 21, 2018
|
| Locations: |
Covance Clinical Research Unit, Madison, Wisconsin, United States
|
| URL: |
https://ClinicalTrials.gov/show/NCT03748628
|
